Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 33.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,952 shares of the biotechnology company’s stock after selling 36,855 shares during the quarter. Guggenheim Capital LLC’s holdings in Exelixis were worth $2,496,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of EXEL. XTX Topco Ltd purchased a new position in shares of Exelixis during the 4th quarter worth $1,031,000. CreativeOne Wealth LLC grew its stake in shares of Exelixis by 53.1% in the 4th quarter. CreativeOne Wealth LLC now owns 12,000 shares of the biotechnology company’s stock valued at $400,000 after buying an additional 4,163 shares during the period. Mariner LLC raised its position in shares of Exelixis by 13.1% during the 4th quarter. Mariner LLC now owns 20,373 shares of the biotechnology company’s stock valued at $678,000 after buying an additional 2,355 shares during the period. Barclays PLC grew its position in Exelixis by 8.9% in the fourth quarter. Barclays PLC now owns 348,009 shares of the biotechnology company’s stock worth $11,587,000 after acquiring an additional 28,420 shares during the period. Finally, Summit Investment Advisors Inc. increased its stake in Exelixis by 28.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 75,200 shares of the biotechnology company’s stock worth $2,504,000 after acquiring an additional 16,677 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of EXEL stock opened at $36.19 on Friday. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $40.02. The firm has a fifty day moving average of $36.44 and a two-hundred day moving average of $34.30. The firm has a market cap of $10.13 billion, a P/E ratio of 20.45, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Insiders Place Their Bets

In other Exelixis news, EVP Patrick J. Haley sold 52,636 shares of the business’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the sale, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the transaction, the director now owns 30,406 shares in the company, valued at $1,060,561.28. This represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 140,343 shares of company stock valued at $5,177,234. Company insiders own 2.85% of the company’s stock.

Wall Street Analyst Weigh In

EXEL has been the subject of a number of recent analyst reports. UBS Group reiterated an “underperform” rating on shares of Exelixis in a research report on Thursday. Oppenheimer downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $41.00 to $33.00 in a report on Friday, January 24th. Stifel Nicolaus upped their price target on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research note on Wednesday, February 12th. Wells Fargo & Company restated a “market outperform” rating on shares of Exelixis in a research report on Thursday. Finally, Royal Bank of Canada boosted their price objective on Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, March 13th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $37.59.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.